BlossomHill Therapeutics Inc(BLSM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 28.93% | Shs Outstand | 31.8M | Perf Week | 2.23% |
| Market Cap | 0.50B | Forward P/E | - | EPS next Y | - | Insider Trans | 20.65% | Shs Float | 22.6M | Perf Month | -38.22% |
| Enterprise Value | 0.68B | PEG | - | EPS next Q | -0.87 | Inst Own | 20.63% | Short Float | 2.1% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 16.1% | Short Ratio | 1.93 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.47M | Perf YTD | -0.95% |
| Book/sh | -5.5 | P/C | 5.2 | EPS past 3/5Y | - | ROE | - | 52W High | -44.27% ($27.99) | Perf Year | - |
| Cash/sh | 3 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 20.65% ($12.93) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 8.44% 10.01% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.61 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.26 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 40.81 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.26 | Sales Q/Q | - | SMA20 | -10.64% ($17.46) | Beta | - | Target Price | $35.4 |
| Payout | - | Debt/Eq | - | Earnings | 2026/9/18 | SMA50 | -18.25% ($19.08) | Rel Volume | 0.31 | Prev Close | $14.4 |
| Employees | 63 | LT Debt/Eq | - | EPS/Sales Surpr. | -844.92% - | SMA200 | -17.54% ($18.92) | Avg Volume(3M) | 0.24M | Price | $15.6 |
| IPO | 2026/8/7 | Option/Short | No/Yes | Trades | 1173 | Volume | 76,273 | Change | 8.33% |
A US clinical-stage biotech company developing small-molecule oncology drugs based on chemistry-driven design. Founded in 2020 and headquartered in San Diego, California, the company is clinically validating drug candidates that target resistance issues of existing therapies in lung cancer and hematologic malignancies.
Over the past 1 year, on the lower side
44% below its 1-year high.
Traded less than usual. That is 31% of its average volume.
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 20.6%.
Tap to view numbers
It ranks #219 of 595 in the industry
Based on market cap of $496M.
DRUG#218 Bright Minds Biosciences Inc $498M PER - BLSM#219 BlossomHill Therapeutics Inc $496M PER - 
ARVN#220 Arvinas Inc $494M PER 47.1 
CBIO#221 Crescent Biopharma Inc $489M PER - 
OCS#222 Oculis Holding AG $486M PER - 
FAQ
What kind of company is BLSM?
BLSM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BLSM?
The market cap of BLSM is approximately $496M, ranking 3,155 within its sector.
What is the 52-week high and low for BLSM?
BLSM has recorded a 52-week high of $27.99 and a low of $12.93.
